Premium
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares will...
Company is committed to evaluating use of the broad-spectrum antiviral in the early treatment setting of COVID-19 to shorten the time to clinical recovery in adult patients with mild to moderate...
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its leadership team will...
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational...
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares listed...
U.S. expansion of antiviral outbreak control trial in long-term care facilities Favipiravir already approved in India and Russia for emergency use against COVID-19 and as a pandemic influenza...
Site screening is required in advance of potential outbreaks in Ontario long-term care centers Only trial in the world investigating use of favipiravir as preventative measure against COVID-19...
Company well-capitalized, reporting record level of capital support with over $27M CAN in equity financings Pipeline portfolio strengthened with initiation of unique COVID-19 clinical study...
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”) is pleased to announce today that its common shares began trading on the OTCQX Best Market®. The OTCQX Market...
Appili program designed to address the most urgent aspects of the COVID-19 public health threat First clinical study to examine the use of favipiravir for COVID-19 outbreak control; National...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
| 52 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
| 156 | 0 | 0 | 1.09 | 1.09 | 1.09 | 0 | 0 | CS |
| 260 | 0.51 | 87.9310344828 | 0.58 | 1.89 | 0.5 | 18072 | 1.16884399 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
